CLINICAL TRIAL article
Front. Med.
Sec. Dermatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1604012
Topical EOSSKY Fullerene Moisturizing and Repairing Cream for Preventing Acute Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy: A Randomized Controlled Trial
Provisionally accepted
- 1Shanxi Medical University, Taiyuan, China
- 2Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
- 3Center for Future High Energy Physics, Institute of High Energy Physics (CAS), Beijing, Beijing Municipality, China
- 4Guangdong-Hong Kong-Macao Greater Bay Area National Institute of Nanotechnology Innovation and Research, Guang Dong, China
- 5Guangzhou Guangna Huichuan Technology Co, guangdong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acute radiation dermatitis (ARD) is a prevalent complication among breast cancer patients undergoing radiotherapy. Fullerene possesses broad-spectrum free radical scavenging properties, which may be beneficial in mitigating oxidative stress. This study aimed to evaluate the impact of fullerene on both the incidence and severity of ARD in breast cancer patients.This study involved 88 breast cancer patients who met the inclusion criteria.Participants were randomly assigned to either the fullerene group or the control group in a 1:1 ratio. The primary endpoint was the grading of ARD and the cumulative dose of ionizing radiation at the first occurrence of ARD. Secondary endpoints included patient-reported symptoms, such as pain and quality of life(QoL).The RTOG score was significantly lower in the fullerene group than in the control group, and the cumulative dose of ionizing radiation at the first occurrence of ARD was higher. There was a statistically significant difference between the two groups (P ＜ 0.05). Regarding the secondary endpoints, the pain scores exhibited a significant reduction in the fullerene group as compared with the control group (P < 0.05). The results of the Skindex-16 scale showed that the quality of life was better in the fullerene group than in the control group (P < 0.01).This trial indicated that fullerene could reduce the grading of ARD, delay the occurrence of ARD, alleviate patients' symptoms, and improve the patients' overall quality of life.
Keywords: Fullerene, Acute radiation dermatitis, Radiotherapy, breast cancer, randomized controlled trial
Received: 01 Apr 2025; Accepted: 29 Jun 2025.
Copyright: © 2025 王, Shi, Guo, Gu, Dong and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinli Guo, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.